A Phase 1 study of 18 patients with severe osteoarthritis of the knee has shown that a single injection of stem cells derived from the patients’ own adipose tissue was safe and appeared to offer relief from pain.
Vedanta Bioscience Inc has raised $50 million in equity finance to advance candidate therapies targeting the human microbiome for the treatment of infectious and autoimmune diseases.
Ablynx NV, a Belgian developer of antibody fragments originating in llamas, has raised €74.2 million with a private placement of new shares.
Life Sciences Partners BV has closed its fifth fund, LSP 5, with a total investment of $280 million, comfortably higher than its initial target of $170 million. The fund will aim to invest in around 20 companies across the healthcare sector.
Novacyt SA, a listed French cellular diagnostics company, has raised €1.4 million from a private equity placement in order to help finance the expansion of its recently acquired UK company Primerdesign, which has technology for analysing bacteria and viruses.
Shire Plc completed its acquisition of Baxalta Inc on 3 June to create a global company focused on developing drugs for rare diseases and other specialised conditions. The $32 billion deal comprises payments in both cash and Shire equity.
Researchers at KU Leuven in Belgium have used cell cultures to show that a prospective antiretroviral medicine called LEDGIN has the potential to put HIV-1 into remission. The research will still need to be tested in mice before it can progress to humans.
Ryboquin Ltd, a virtual Scottish company with no salaried employees, has raised £1.3 million for the scaling up production of its lead product, Ryboquin ECP-102, which boosts the effectiveness of chemotherapy in cancer patients.
Nouscom SA, a new developer of cancer vaccines raised €12 million in a Series A financing round earlier this month to support the development of a portfolio of products based on oncolytic viruses and viral vectors. The company is based in Basel, Switzerland.
The European Medicines Agency has launched a review of guidelines for the testing of new medicines in volunteers following the death of one person and the hospitalisation of five others in France in January. The case is the most serious incident to come to light since 2006 when an experimental immunotherapy seriously injured six volunteers in a first-in-human study the UK.